

Core facility for crystallographic and biophysical research to support the development of medicinal products

J. Kutner, M.. Górna and K. Woźniak

Core Facility for Crystallography and Biophysics, Biological and Chemical Research Centre, Department of Chemistry, University of Warsaw, Zwirki i Wigury 101, 02-089 Warszawa, Poland, cfcbuw@cnbc.uw.edu.pl

The project “*Core facility for crystallographic and biophysical research to support the development of medicinal products*” is funded by the **TEAM-TECH Core Facility** programme from the **Foundation for Polish Science** (www.fnp.org.pl). The project will establish a **Core Facility for Crystallography and Biophysics** (CFCB UW) at the Biological and Chemical Research Centre, University of Warsaw under the supervision of **Prof. dr hab. Krzysztof Woźniak** (crystal.chem.uw.edu.pl).

The mission of the new Facility is focused on analysis of proteins and small chemical compounds (molecules) leading to crystallization trials for academic and commercial users. The project will enable the study of challenging biochemical and pharmaceutical problems, with emphasis on drug development and collaborations with the local research groups. Work at CFCB UW will be carried out in an interdisciplinary way, including both wet biology (“**BIO**”) and chemical crystallography (“**CHEM**”) techniques as well as theoretical approaches including structure modelling, bioinformatics and computational methods (Figure 1.). Biology and chemistry team members will work in synergy complementing their knowledge, skills and experience. Apart from services and collaborations, postdoctoral and PhD researchers are expected to carry out their own research projects dedicated either to small-molecule or protein crystallography.




Figure 1: Schematic view of the main pipelines of the Core Facility for Crystallography and Biophysics (CFCB UW).

Young scientists working in the project will benefit from mentoring and exchange visits with the project partners, Prof. Wlodek Minor (University of Virginia, USA) and Prof. Ben Luisi (University of Cambridge, UK). Work at CFCB will include, among others, collaboration with biotech/pharmaceutical companies, such as the WPD Pharmaceuticals or the Pharmaceutical Institute in Warsaw (Poland).